References
- Duggan DB, Petroni GR, Johnson JL, . Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607–614.
- Aparicio J, Segura A, Garcera S, . ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 1999;10:593–595.
- Stiff PJ, Unger JM, Forman SJ, . The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003;9:529–539.
- Moskowitz CH, Nimer SD, Zelenetz AD, . A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616–623.
- Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007;26:1351–1356.
- Kelly WK, Richon VM, O'Connor O, . Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9:3578–3588.
- Watanabe T, Kato H, Kobayashi Y, . Potential efficacy of the oral histonedeacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 2010;101:196–200.
- Kirschbaum M, Frankel P, Popplewell L. . Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:1198–1203.
- Cheson BD, Horning SJ, Coiffier B, . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
- Green SJ, and S. Planned versus attained design in phase II clinical trials. Stat Med 1992;11:853–862.
- Zhao Y, Lu S, Wu L, . Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 2006;26:2782–2790.
- Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 2009;280:145–153.
- Maeda T, Towatari M, Kosugi H, . Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 2000;96:3847–3856.
- Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009;280:125–133.
- Richon VM, Sandhoff TW, Rifkind RA, . Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000;97:10014–10019.
- Scuto A, Kirschbaum M, Kowolik C, . The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood 2008;111:5093–5100.
- Li N, Zhao D, Kirschbaum M, . HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc Natl Acad Sci USA 2008;105:4796–4801.
- Kretzner L, Scuto A, Dino PM, . Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and micro-RNA levels. Cancer Res 2011;71:3912–3920.
- Buglio D, Georgakis GV, Hanabuchi S, . Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008;112:1424–1433.
- Robert C, Ajay KG, Scott ES, . Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts), Nov 2010;116:283.
- Younes A, Bociek RG, Kuruvilla J, . Mocetinostat (MGCD0103), an isotype-selective histone deacetylase (HDAC) inhibitor, produces clinical responses in relapsed/refractory Hodgkin lymphoma (HL): update from a phase II clinical study. Blood 2010;116(Suppl. 1): Abstract 1763.
- Sureda A, Engert A, Browett PJ, . Interim results for the phase II study of panobinostat (LBH589) in patients (Pts) with relapsed/refractory Hodgkin's lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT). J Clin Oncol 2010;28(15 Suppl.): Abstract 8007.
- O'Connor OA, Heaney ML, Schwartz L, . Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006;24:166–173.